LONDON (Alliance News) - Faron Pharmaceuticals Oy on Tuesday said it has filed two new patent applications for Clevegen, its cancer immunotherapy drug candidate.
Faron said the patents, filed in Finland, are expected to be expanded to most countries over the next two few years under the Patent Co-operation Treaty.
"We are very excited about these new filings. The new patents, if granted, will provide a significant extension to our strong intellectual property coverage on Clever-1 and presents new opportunities for Clevegen, which also has the potential to be used in combination therapies with other immune checkpoint compounds," said Faron Chief Executive Markku Jalkanen.
"We believe that Clevegen also has the potential for use in chronic infections as well as vaccination protocols, both of which are dependent on immune balance between activation and suppression," he added.
Faron shares were untraded on Tuesday morning, having last traded at 250.00 pence.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Faron Pharmaceuticals (FARN)